Hyloris Developmentsen Sa Total Assets
Hyloris Developmentsen Sa total assets. Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) holds total assets worth €37.05 Million EUR (≈ $43.32 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Hyloris Developmentsen Sa for the company's overall valuation and market capitalisation.
Total Assets of Hyloris Developmentsen Sa (2016–2024)
Total assets of Hyloris Developmentsen Sa from 2016 to 2024. This chart illustrates how Hyloris Developmentsen Sa's total assets have evolved over time, based on quarterly financial data. See Hyloris Developmentsen Sa stock price for real-time trading data and today's change.
Hyloris Developmentsen Sa - Asset Composition Analysis
Hyloris Developmentsen Sa Total Assets Breakdown (December 2024)
Hyloris Developmentsen Sa total assets breakdown as of December 2024. Hyloris Developmentsen Sa's total assets of €37.05 Million consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 57.1% |
| Accounts Receivable | €4.86 Million | 11.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.84 Million | 9.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Hyloris Developmentsen Sa's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hyloris Developmentsen Sa working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hyloris Developmentsen Sa's current assets represent 71.9% of total assets in 2024, an increase from 21.2% in 2016.
- Cash Position: Cash and equivalents constituted 57.1% of total assets in 2024, up from 16.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.8% of total assets.
Hyloris Developmentsen Sa Competitors by Total Assets
Key competitors of Hyloris Developmentsen Sa based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
China | CN¥2.88 Billion |
Hyloris Developmentsen Sa - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.82 | 3.71 | 31.24 |
| Quick Ratio | 3.80 | 3.71 | 31.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €17.86 Million | €23.94 Million | €64.48 Million |
Hyloris Developmentsen Sa - Advanced Valuation Insights
This section examines the relationship between Hyloris Developmentsen Sa's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.09 |
| Latest Market Cap to Assets Ratio | 2.99 |
| Asset Growth Rate (YoY) | -13.3% |
| Total Assets | €41.34 Million |
| Market Capitalization | $123.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Hyloris Developmentsen Sa's assets at a significant premium (2.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Hyloris Developmentsen Sa's assets decreased by 13.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hyloris Developmentsen Sa (2016–2024)
The table below shows the annual total assets of Hyloris Developmentsen Sa from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €41.34 Million ≈ $48.32 Million |
-13.31% |
| 2023-12-31 | €47.68 Million ≈ $55.74 Million |
-22.93% |
| 2022-12-31 | €61.86 Million ≈ $72.33 Million |
-2.49% |
| 2021-12-31 | €63.44 Million ≈ $74.17 Million |
-8.29% |
| 2020-12-31 | €69.18 Million ≈ $80.88 Million |
+1056.31% |
| 2019-12-31 | €5.98 Million ≈ $6.99 Million |
-24.72% |
| 2018-12-31 | €7.95 Million ≈ $9.29 Million |
+82.08% |
| 2017-12-31 | €4.37 Million ≈ $5.10 Million |
+224.54% |
| 2016-12-31 | €1.34 Million ≈ $1.57 Million |
-- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more